News Column

Findings in Engineering Reported from Weill Cornell Medical College (Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells)

July 21, 2014

By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Current study results on Engineering have been published. According to news reporting originating in New York City, New York, by NewsRx journalists, research stated, "T-cell therapies using engineered T cells show great promise for cancer immunotherapy, as illustrated by the CD19 paradigm. Much of the excitement about this approach, and second-generation CARs in particular, is due to the dramatic clinical results recently reported by a few centers, especially in acute lymphoblastic leukemia, and the applicability of this approach, in principle, to a wide range of cancers."

The news reporters obtained a quote from the research from Weill Cornell Medical College, "Extending the use of CAR therapies to cancers other than B-cell malignancies will require selective tumor targeting with minimal or acceptable 'on-target, off-tumor' effects. The identification of new CAR target antigens is thus one of the next big challenges to address. Recognizing the paucity of currently available tumor-specific targets, we have developed broadly applicable approaches to enhance the tumor selectivity and safety of engineered T cells. Here, we review 2 promising concepts. One is to improve tumor targeting based on combinatorial antigen recognition."

According to the news reporters, the research concluded: "The other uses receptors that provide antigen-specific inhibition, which we named iCARs, to divert T cells from the normal tissues one wants to protect."

For more information on this research see: Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells. Cancer Journal, 2014;20(2):160-165. Cancer Journal can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA (see also Engineering).

Our news correspondents report that additional information may be obtained by contacting V.D. Fedorov, Weill Cornell Med College, Dept. of Med Genet, New York, NY, United States. Additional authors for this research include M. Sadelain and C.C. Kloss.

Keywords for this news article include: Engineering, New York City, United States, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Cancer Vaccine Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters